Last reviewed · How we verify
Gluteus triamcinolone
Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and rheumatologic conditions requiring intramuscular corticosteroid therapy, Allergic and dermatologic disorders.
At a glance
| Generic name | Gluteus triamcinolone |
|---|---|
| Also known as | gluteus maximus infiltration with triamcinolone. |
| Sponsor | Hospital de Braga |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Dermatology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone exerts its anti-inflammatory effects through glucocorticoid receptor activation, which leads to decreased production of inflammatory mediators such as cytokines, chemokines, and adhesion molecules. When administered via gluteal intramuscular injection, it provides sustained local and systemic anti-inflammatory and immunosuppressive effects, making it useful for managing inflammatory and autoimmune conditions.
Approved indications
- Inflammatory and rheumatologic conditions requiring intramuscular corticosteroid therapy
- Allergic and dermatologic disorders
Common side effects
- Injection site pain or irritation
- Hyperglycemia
- Insomnia
- Mood changes
- Immunosuppression
Key clinical trials
- Symptom Clusters in Children With Exacerbation-prone Asthma (PHASE2)
- Feasibility of a Home Exercise Program With the Addition of a Corticosteroid Injection in Patients With Lateral Hip Pain (NA)
- Caudal Epidural Steroid and Trigger Point Injection (PHASE4)
- Efficacy of Corticoid Infiltration in Quadratus Lumborum Syndrome (PHASE4)
- Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gluteus triamcinolone CI brief — competitive landscape report
- Gluteus triamcinolone updates RSS · CI watch RSS
- Hospital de Braga portfolio CI